Posted on Wednesday, 30 June 2010 by
PR Newswire: Health
SEATTLE, June 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced that the Centers for Medicare and Medicaid Services (CMS) today initiated a National Coverage Analysis (NCA) of PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymp
Read the full article at PR Newswire: Health